US Patent Litigations are now available. Check here

Explore Kandy Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jun 12, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3765024Nov 22, 2023Novel Pharmaceutical Formulation Comprising Dual Nk-1/Nk-3 Receptor Antagonists1
EP3574907Aug 23, 2023An Nk-1/Nk-3 Receptor Antagonist For The Treatment Of Sex-Hormone-Dependent Diseases1